Philippe B. Ruszniewski
#134,882
Most Influential Person Now
Philippe B. Ruszniewski's AcademicInfluence.com Rankings
Philippe B. Ruszniewskiphilosophy Degrees
Philosophy
#6752
World Rank
#9847
Historical Rank
Logic
#3874
World Rank
#5098
Historical Rank
Download Badge
Philosophy
Philippe B. Ruszniewski's Degrees
- Doctorate Medicine Université Paris Cité
- PhD Medical Sciences Université Paris Cité
Why Is Philippe B. Ruszniewski Influential?
(Suggest an Edit or Addition)Philippe B. Ruszniewski's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011) (2225)
- Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors (2017) (1823)
- Gastroenteropancreatic neuroendocrine tumours. (2008) (1504)
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014) (661)
- Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial (2010) (647)
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. (2004) (561)
- Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. (2007) (484)
- Risk of pancreatic adenocarcinoma in chronic pancreatitis (2002) (444)
- Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. (2001) (408)
- Intraductal Papillary Mucinous Tumors of the Pancreas Confined to Secondary Ducts Show Less Aggressive Pathologic Features as Compared With Those Involving the Main Pancreatic Duct (2000) (403)
- ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms (2016) (347)
- Assessment of complications of EUS-guided fine-needle aspiration. (2001) (328)
- Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours (2004) (323)
- Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. (2010) (294)
- ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms (2011) (281)
- Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma (2002) (280)
- Neuroendocrine tumors of midgut and hindgut origin: Tumor‐node‐metastasis classification determines clinical outcome (2011) (279)
- Pancreatic involvement in von Hippel–Lindau disease (2000) (276)
- Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors a prospective phase II study in 24 patients (1993) (269)
- The natural history of hereditary pancreatitis: a national series (2008) (267)
- Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients (2010) (266)
- Preoperative cyst fluid analysis is useful for the differential diagnosis of cystic lesions of the pancreas. (1995) (255)
- Prognostic factors in patients with endocrine tumours of the duodenopancreatic area (1998) (254)
- Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses (2000) (254)
- Risk of Pancreatic Adenocarcinoma in Patients With Hereditary Pancreatitis: A National Exhaustive Series (2008) (254)
- Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. (2009) (232)
- Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression (2004) (229)
- Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. (2002) (228)
- Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. (2018) (226)
- Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. (2006) (226)
- Treatment of carcinoid syndrome (2000) (218)
- ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms (2016) (215)
- Risk factors for diabetes mellitus in chronic pancreatitis. (2000) (215)
- Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. (1999) (207)
- Hereditary pancreatitis caused by triplication of the trypsinogen locus (2006) (205)
- Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. (1996) (200)
- Acute Pancreatitis in a Cohort of 129 Patients Referred for Severe Hypertriglyceridemia (2008) (194)
- Pancreas Divisum Is Not a Cause of Pancreatitis by Itself But Acts as a Partner of Genetic Mutations (2012) (192)
- Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. (2013) (192)
- Microadenomatosis of the Endocrine Pancreas in Patients With and Without the Multiple Endocrine Neoplasia Type 1 Syndrome (2006) (192)
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours (2017) (186)
- The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors (2000) (185)
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study (2016) (179)
- Laparoscopic pancreaticoduodenectomy should not be routine for resection of periampullary tumors. (2015) (174)
- Outcome of Patients With Type 1 or 2 Autoimmune Pancreatitis (2011) (173)
- Long-term Outcome of Biliary and Duodenal Stents in Palliative Treatment of Patients with Unresectable Adenocarcinoma of the Head of Pancreas (2006) (166)
- Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. (2000) (162)
- Prognostic Factors in Patients With Zollinger-Ellison Syndrome and Multiple Endocrine Neoplasia Type 1 (1999) (160)
- Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. (2003) (157)
- High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. (2013) (157)
- Predictors of Long‐Term Survival After Liver Transplantation for Metastatic Endocrine Tumors: An 85‐Case French Multicentric Report (2008) (156)
- Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis (2000) (156)
- Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN) (2015) (154)
- Determination of the relative contribution of three genes–the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene–to the etiology of idiopathic chronic pancreatitis (2002) (152)
- Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference (2014) (152)
- Well-Differentiated Gastric Tumors/Carcinomas (2007) (150)
- Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide (2004) (149)
- Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. (2012) (148)
- Predictive factors in the outcome of pseudocysts complicating alcoholic chronic pancreatitis (1997) (147)
- Intraductal papillary mucinous tumors of the pancreas: the preoperative value of cytologic and histopathologic diagnosis. (2003) (147)
- Macrocystic pancreatic cystadenoma: The role of EUS and cyst fluid analysis in distinguishing mucinous and serous lesions. (2004) (144)
- Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. (1992) (141)
- Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). (2013) (138)
- Endocrine Pancreatic Tumours and Helical CT: Contrast Enhancement Is Correlated with Microvascular Density, Histoprognostic Factors and Survival (2006) (131)
- Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. (2006) (131)
- Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. (1989) (130)
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. (2012) (130)
- Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. (1995) (128)
- Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA (2002) (127)
- Expression of hypoxia‐inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas (2005) (125)
- Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. (1996) (124)
- Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). (2006) (123)
- Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? (2006) (121)
- Intraductal papillary mucinous tumors of the pancreas: pancreatic resections guided by preoperative morphological assessment and intraoperative frozen section examination. (2000) (120)
- Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. (2016) (119)
- MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines. (2015) (119)
- Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine Tumors (2000) (119)
- Intraductal Papillary Mucinous Neoplasms of the Pancreas: Performance of Pancreatic Fluid Analysis for Positive Diagnosis and the Prediction of Malignancy (2008) (118)
- Pancreaticoduodenectomy with Mesentericoportal Vein Resection for Adenocarcinoma of the Pancreatic Head (2006) (117)
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers (2017) (116)
- Two-step Surgery for Synchronous Bilobar Liver Metastases From Digestive Endocrine Tumors: A Safe Approach for Radical Resection (2008) (110)
- Mucin gene expression in intraductal papillary‐mucinous pancreatic tumours and related lesions (2002) (109)
- Diagnostic value of CA 72–4 and carcinoembryonic antigen determination in the fluid of pancreatic cystic lesions (1998) (105)
- Frozen Sectioning of the Pancreatic Cut Surface During Resection of Intraductal Papillary Mucinous Neoplasms of the Pancreas Is Useful and Reliable: A Prospective Evaluation (2005) (103)
- Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. (2011) (102)
- Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours (2000) (102)
- Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (2017) (102)
- Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. (1993) (101)
- Incidence and reversibility of organ failure in the course of sterile or infected necrotizing pancreatitis. (2001) (99)
- Splenic complications in chronic pancreatitis: prevalence and risk factors in a medical–surgical series of 500 patients (1998) (97)
- Impact of total pancreatectomy: short- and long-term assessment. (2013) (96)
- Effects of a multimodal management strategy for acute mesenteric ischemia on survival and intestinal failure. (2013) (96)
- Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours (2006) (94)
- Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. (2005) (93)
- Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. (2004) (93)
- The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. (2006) (93)
- Parenchyma-Sparing Resections for Pancreatic Neuroendocrine Tumors (2012) (93)
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors (2009) (92)
- Reappraisal of central pancreatectomy a 12-year single-center experience. (2014) (91)
- Clinical, Anatomical, and Evolutive Features of Patients with the Zollinger‐Ellison Syndrome Combined with Type I Multiple Endocrine Neoplasia (1993) (89)
- The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas. (2012) (89)
- Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system (1998) (88)
- Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors (2008) (87)
- An overview of hereditary pancreatitis. (2012) (87)
- Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study (2012) (86)
- Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis (2002) (86)
- Diagnostic Criteria in Predicting a Biliary Origin of Acute Pancreatitis in the Era of Endoscopic Ultrasound: Multicentre Prospective Evaluation of 213 Patients (2005) (86)
- A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial (2017) (85)
- Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. (2013) (85)
- ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update (2011) (85)
- Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. (2014) (85)
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study (2016) (84)
- Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin (2007) (83)
- Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors (2009) (83)
- Clinical and Morphological Features of Duodenal Cystic Dystrophy in Heterotopic Pancreas (2007) (83)
- Chemotherapy for Gastro-Enteropancreatic Endocrine Tumours (2004) (82)
- Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study. (2013) (81)
- Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. (2018) (80)
- Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. (2009) (80)
- Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. (2009) (80)
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. (2016) (79)
- Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis (2001) (77)
- Cystic Dystrophy of the Duodenal Wall in the Heterotopic Pancreas: Radiopathological Correlations (2000) (76)
- Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. (2016) (74)
- Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France (2008) (72)
- MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. (2016) (71)
- The Largest European Single-Center Experience: 300 Laparoscopic Pancreatic Resections. (2017) (71)
- Endocrine Pancreatic Tumors in von Hippel-Lindau Disease: Clinical, Histological, and Genetic Features (2008) (71)
- Somatostatin receptor subtype gene expression in human endocrine gastroentero‐pancreatic tumours (1997) (71)
- Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study (2018) (71)
- Parenchyma-Sparing Pancreatectomy for Presumed Noninvasive Intraductal Papillary Mucinous Neoplasms of the Pancreas (2014) (70)
- Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. (2006) (70)
- Hepatobiliary and Pancreatic neoplasms in patients with McCune-Albright syndrome. (2014) (70)
- Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. (2010) (69)
- Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. (2021) (69)
- Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors (2013) (69)
- Ablative therapies for liver metastases of digestive endocrine tumours. (2003) (66)
- Development of gastric argyrophil carcinoid tumors in a case of zollinger‐ellison syndrome with primary hyperparathyroidism during long‐term antisecretory treatment (1987) (66)
- NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate. (2016) (65)
- Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study (2017) (64)
- Immunoglobulin G4 immunostaining of gastric, duodenal, or colonic biopsies is not helpful for the diagnosis of autoimmune pancreatitis. (2012) (64)
- Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. (2009) (64)
- Mucinous Cystic Neoplasms of the Pancreas: Definition of Preoperative Imaging Criteria for High-Risk Lesions (2011) (64)
- Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (2018) (64)
- Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability. (2007) (63)
- Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. (2009) (62)
- Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis. (2014) (61)
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. (2021) (61)
- Effects of Esomeprazole on Acid Output in Patients With Zollinger-Ellison Syndrome or Idiopathic Gastric Acid Hypersecretion (2007) (60)
- Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). (2020) (59)
- Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I (1993) (58)
- Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. (2012) (57)
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020) (57)
- Is idiopathic chronic pancreatitis an autoimmune disease? (2005) (57)
- Reappraisal of pancreatic enucleations: A single-center experience of 126 procedures. (2015) (57)
- Prevalence of Extrapancreatic Cancers in Patients With Histologically Proven Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Case–Control Study (2008) (56)
- Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. (2012) (56)
- ENETS Consensus Guidelines for the Management of Peritoneal Carcinomatosis from Neuroendocrine Tumors (2010) (54)
- Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. (2010) (53)
- Smoking and the Course of Recurrent Acute and Chronic Alcoholic Pancreatitis: A Dose-Dependent Relationship (2012) (53)
- Staging of Pancreatic Head Adenocarcinoma with Spiral CT and Endoscopic Ultrasonography: An Indirect Evaluation of the Usefulness of Laparoscopy (2004) (53)
- Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients (2012) (52)
- Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). (1997) (52)
- Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. (2015) (52)
- Peritoneal carcinomatosis in patients with digestive endocrine tumors (1996) (52)
- Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease: Characterization by VHL/HIF Pathway Proteins Expression (2009) (50)
- Gemcitabine in elderly patients with advanced pancreatic cancer. (2011) (50)
- Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? (2009) (49)
- Toward a Preoperative Classification of Lymph Node Metastases in Patients with Small Intestinal Neuroendocrine Tumors in the Era of Intestinal-Sparing Surgery (2015) (48)
- 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial (2015) (47)
- Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases (2018) (46)
- Mortality Rate and Risk Factors in Patients With Hereditary Pancreatitis: Uni- and Multidimensional Analyses (2009) (46)
- Ablative Therapies for Liver Metastases of Gastroenteropancreatic Endocrine Tumors (2004) (45)
- CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. (2006) (45)
- Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). (2001) (45)
- Acute Pancreatitis in Patients Operated on for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Frequency, Severity, and Clinicopathologic Correlations (2010) (44)
- Intraductal acinar cell carcinoma of the pancreas (2008) (43)
- Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors (2015) (42)
- High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. (2016) (41)
- Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics? (2015) (41)
- Endocrine Tumor and Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Fortuitous Association? (2005) (41)
- FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. (2012) (40)
- 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial (2016) (40)
- Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. (2011) (40)
- Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. (2010) (40)
- Macrocystic form of serous pancreatic cystadenoma. (2002) (39)
- Calcitonin‐Secreting Tumors of the Pancreas: About Six Cases (1998) (39)
- Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. (2016) (39)
- Chronic esophagitis dissecans: an unrecognized clinicopathologic entity? (1997) (39)
- Nonsteroidal anti‐inflammatory drug use as a risk factor for gastro‐oesophageal reflux disease: an observational study (2008) (38)
- Extrahepatic Portal Venous System Thrombosis in Recurrent Acute and Chronic Alcoholic Pancreatitis Is Caused by Local Inflammation and Not Thrombophilia (2012) (38)
- Diagnosis and management of pancreatic fistulae resulting in pancreatic ascites or pleural effusions in the era of helical CT and magnetic resonance imaging. (2007) (38)
- Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study (2011) (38)
- Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. (2021) (37)
- Detection of gastric mucins (M1 antigens) in cyst fluid for the diagnosis of cystic lesions of the pancreas (1997) (37)
- Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms: : GNAS-activating mutations in pancreatic carcinogenesis. (2014) (36)
- Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors. (2019) (36)
- Long‐Acting Somatostatin (SMS 201‐995) in the Management of Zollinger‐Ellison Syndrome: Evidence for Sustained Efficacy (1988) (36)
- Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor (2019) (36)
- Liver transarterial embolizations in metastatic neuroendocrine tumors (2017) (35)
- Squamous cell carcinoma and lipomatous pseudohypertrophy of the pancreas (1999) (35)
- Ulcerative colitis in a sigmoid neovagina. (2000) (35)
- Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. (2008) (35)
- Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). (2018) (35)
- Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms (2018) (35)
- Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. (2017) (35)
- PROLONGED TREATMENT OF ZOLLINGER-ELLISON SYNDROME BY LONG-ACTING SOMATOSTATIN (1986) (34)
- A new large CFTR rearrangement illustrates the importance of searching for complex alleles (2006) (34)
- Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines (2017) (34)
- Do guidelines influence medical practice? Changes in management of acute pancreatitis 7 years after the publication of the French guidelines (2012) (33)
- Long‐term treatment with octreotide in patients with the Zollinger‐ElIison syndrome (1993) (33)
- Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. (2021) (33)
- The burden cost of French patients suffering from irritable bowel syndrome (2004) (33)
- Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective (2019) (33)
- Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (2018) (32)
- Surgery for small-bowel neuroendocrine tumors: Is there any benefit of the laparoscopic approach? (2013) (32)
- Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis. (2009) (32)
- Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (2018) (32)
- Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas (2016) (31)
- Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation (2015) (31)
- Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? (2015) (31)
- Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). (2012) (31)
- Macrocystic form of serous pancreatic cystadenoma (2002) (30)
- Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) (30)
- Natural history of SPINK1 germline mutation related-pancreatitis (2019) (30)
- Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma (2012) (30)
- Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process (2018) (30)
- Right intrahepatic pseudocyst following acute pancreatitis: an unusual location after acute pancreatitis. (2005) (30)
- [Intraductal papillary mucinous tumors of the pancreas. Clinical and morphological aspects in 30 patients]. (1997) (30)
- Diagnostic challenge in autoimmune pancreatitis: beware of shipwreck! (2008) (29)
- NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results. (2016) (29)
- Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion? (2014) (29)
- Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses (2019) (29)
- Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. (1996) (28)
- Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract (2012) (28)
- Current approach to the management of tumoral process in patients with gastrinoma (1986) (27)
- Co-inheritance of a novel deletion of the entire SPINK1 gene with a CFTR missense mutation (L997F) in a family with chronic pancreatitis. (2007) (27)
- Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'étude des Tumeurs Endocrines study. (2015) (27)
- Sunitinib in pancreatic neuroendocrine tumors (2012) (27)
- Management of Islet Cell Tumors in Patients with Multiple Endocrine Neoplasia Type 1 (1994) (27)
- Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary‐mucinous adenoma (2006) (27)
- Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. (1988) (27)
- Temozolomide: A Safe and Effective Treatment for Malignant Digestive Endocrine Tumors (2009) (27)
- Mixed endocrine somatostatinoma of the ampulla of vater associated with a neurofibromatosis type 1: a case report and review of the literature. (2010) (26)
- Genetic and Electrophysiological Characteristics of Recurrent Acute Pancreatitis (2015) (25)
- Pancreatic intraepithelial neoplasia in patients with intraductal papillary mucinous neoplasms: the interest of endoscopic ultrasonography. (2013) (25)
- Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology (2020) (24)
- Sunitinib paves the way for targeted therapies in neuroendocrine tumors (2009) (24)
- Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors (2015) (24)
- First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (24)
- In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms. (2014) (24)
- High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis (2015) (24)
- [Pancreatic perivascular epithelioid cell tumor (PEComa)]. (2008) (23)
- Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome (1993) (22)
- [Frequency of CFTR gene mutations in idiopathic pancreatitis]. (2008) (22)
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study (2020) (22)
- Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. (1999) (22)
- Neuroendocrine Tumors: A Critical Appraisal of Management Strategies (2010) (22)
- Helical CT of Pancreatic Endocrine Tumors (2002) (21)
- CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs) (2014) (21)
- Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors (2015) (21)
- Hypoxia Pathways and Cellular Stress Activate Pancreatic Stellate Cells: Development of an Organotypic Culture Model of Thick Slices of Normal Human Pancreas (2013) (21)
- Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. (2021) (20)
- [Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients]. (1991) (20)
- [Acinar cystic transformation of the pancreas (or acinar cell cystadenoma), a rare and recently described entity]. (2002) (19)
- Pure laparoscopic middle pancreatectomy: single-center experience with 13 cases (2013) (19)
- Proteomic Assessment of Markers for Malignancy in the Mucus of Intraductal Papillary Mucinous Neoplasms of the Pancreas (2012) (19)
- Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. (2014) (18)
- Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE) (2017) (18)
- 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation (2017) (18)
- Does tobacco influence the natural history of autoimmune pancreatitis? (2014) (17)
- The Expression of the Hypoxia Markers CA9 and CXCR4 Is Correlated with Survival in Patients with Neuroendocrine Tumours of the Ileum (2011) (17)
- Familial intraductal papillary mucinous neoplasms of the pancreas. (2012) (17)
- Dorsal pancreatectomy: An embryology-based resection (2006) (17)
- [Limited pancreatic resections for intraductal papillary mucinous neoplasm]. (2008) (17)
- In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma (2018) (17)
- A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial (2015) (16)
- Primary endocrine tumours of the liver (2005) (16)
- CFTR Gene Mutation in Patients with Apparently Idiopathic Pancreatitis: Lack of Phenotype-Genotype Correlation (2010) (16)
- Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study. (2017) (16)
- Recurrence after surgical resection of gastrinoma: who, when, where and why? (2012) (16)
- Efficacy of Lanreotide 30 mg on Prevention of Pain Relapse after Oral Refeeding in Patients with Necrotizing Acute Pancreatitis (2004) (16)
- Cystic form of paraduodenal pancreatitis (cystic dystrophy in heterotopic pancreas (CDHP)): a potential link with minor papilla abnormalities? A study in a large series (2015) (16)
- Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. (1993) (16)
- Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis (2015) (15)
- [Acute pancreatitis secondary to dengue]. (2005) (15)
- Octreotide (SMS 201–995) inhibits the growth of colon peritoneal carcinomatosis in BDIX rats (1993) (15)
- [Pancreatoblastoma in adults]. (1997) (15)
- Predicting the efficacy of surgery for pain relief in patients with alcoholic chronic pancreatitis (2018) (15)
- EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins (2013) (15)
- Endocrine Tumors of the Pancreatic Area: Localization by Endoscopic Ultrasonography (1994) (14)
- Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals (2019) (14)
- [Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results]. (1995) (14)
- Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms (2021) (14)
- [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. (2005) (14)
- Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. (2019) (13)
- Obesity-induced pancreatopathy in rats is reversible after bariatric surgery (2018) (13)
- [Regression of mesenteric lymph node cavitation syndrome complicating celiac disease after a gluten free diet]. (2000) (13)
- [Epidemiology of gastro-esophageal-reflux in general practice. . Predictive factors for health care utilization in the course of a year]. (1999) (13)
- [Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases]. (2005) (13)
- 1162MO Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (2020) (12)
- Do not biopsy solid pseudopapillary tumors of the pancreas! (2008) (12)
- Hand-assisted laparoscopic total pancreatectomy: a report of two cases. (2013) (12)
- Gastrin secretion by gastrinoma cells in long-term culture. (1988) (12)
- Management of gastric neuro-endocrine tumours in a large French national cohort (GTE) (2017) (12)
- Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database (2017) (12)
- Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. (2013) (12)
- [Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (ETG)]. (2004) (11)
- Recurrent acute pancreatitis caused by association of a novel mutation of the calcium-sensing receptor gene and a heterozygous mutation of the SPINK1 gene. (2010) (11)
- Erratum: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors (Neuroendocrinology (2004) 80 (394-424)) (2005) (11)
- Pancreatic portal cavernoma in patients with cavernous transformation of the portal vein: MR findings (2009) (11)
- Temporary Restoration of Digestive Continuity After Laparoscopic Gastric Bypass to Allow Endoscopic Sphincterotomy and Retrograde Exploration of the Biliary Tract (2010) (11)
- Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. (2016) (11)
- 3464 Eus guided fine needle aspiration biopsy with a new electronic device: results on 100 consecutive patients. (2000) (10)
- The risk of pancreatic adenocarcinoma (PA) in patients (pts) with chronic pancreatitis (CP): Myth or reality? (1998) (10)
- Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locally-advanced (LA) pancreatic cancer patients: Retrospective analysis of 181 patients enrolled in prospective phases II and III GERCOR studies (2005) (10)
- [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome]. (1994) (10)
- Endoscopic management of pancreatic fistula after enucleation of pancreatic tumors (2015) (10)
- New treatment options with cytotoxic agents in neuroendocrine tumours (2012) (10)
- Granular cell tumor of the pancreas. (2005) (9)
- Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. (2018) (9)
- Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas (2013) (9)
- p.Ala541Thr variant of MEN1 gene: a non deleterious polymorphism or a pathogenic mutation? (2014) (9)
- Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms (2020) (9)
- Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study. (2014) (9)
- Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE (2021) (9)
- Management and Prognosis of Localized Duodenal Neuroendocrine Neoplasms (2020) (9)
- Critical appraisal of MGMT in digestive NET treated with alkylating agents. (2020) (9)
- Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible? (2017) (8)
- Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours (1996) (8)
- Irregular Narrowing of the Main Pancreatic Duct in Association With a Wall Thickening Is a Key Sign at Endoscopic Ultrasonography for the Diagnosis of Autoimmune Pancreatitis (2015) (8)
- DNA integrity as biomarker in pancreatic cyst fluid. (2016) (8)
- Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome Comments on P. Salpea and C. Stratakis (2014) (8)
- Plexiform neurofibroma mimicking a pancreatic cystic tumour (2005) (8)
- Epidermoid carcinoma complicating esophageal lichen planus without cutaneous or oral involvement. (2011) (8)
- Imaging IPMN: take home messages and news. (2011) (8)
- NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE. (2016) (8)
- Quality of life scale and impact of a topical treatment on symptoms of gastro-esophageal reflux without severe esophagitis. (2005) (7)
- [Treatment of pancreatic-duodenal endocrine tumors]. (2002) (7)
- Difficult diagnosis of atypical cystic pancreatic lesions in von Hippel-Lindau disease. (2010) (7)
- Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors (2017) (7)
- Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis (2012) (7)
- The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs. (2019) (7)
- Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). (2012) (7)
- Pharmaco‐economic considerations in the long‐term management of peptic ulcer disease (1993) (7)
- Digestive endocrine tumors. (2006) (7)
- Implementation of a large-scale simulation-based cardiovascular clinical examination course for undergraduate medical students – a pilot study (2019) (7)
- A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (2019) (7)
- Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus (2012) (7)
- Impact of integrating objective structured clinical examination into academic student assessment: Large-scale experience in a French medical school (2021) (7)
- Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors (2020) (7)
- [Clinical spectrum of digestive neuroendocrine tumors]. (2002) (6)
- The diagnostic dilemmas in discrimination between pancreatic carcinoma and chronic pancreatitis. (2004) (6)
- Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study. (2015) (6)
- Cystic dystrophy in gastric heterotopic pancreas complicated by intracystic hemorrhage and fistulisation in the stomach - a pediatric case. (2008) (6)
- Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged 65 years: Subgroup analyses from the CLARINET study. (2015) (6)
- Effects of PGE2, misoprostol, and enprostil on guinea pig enterocyte adenylate cyclase (1993) (6)
- Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study. (2016) (6)
- [Are the causes similar for benign and severe forms of acute pancreatitis?]. (2003) (6)
- [Severe thrombopenia as single sign of hemophagocytosis in a patient with cirrhosis and lethal infection of ascitis fluid by Escherichia coli]. (2007) (6)
- NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis (2016) (6)
- [Cost of fibroscopy in gastroduodenal ulcer]. (1992) (6)
- [Intermittent treatment or preventive treatment of recurrence in duodenal ulcer disease? A controlled, double-blind study with 150 mg ranitidine daily for one year]. (1990) (6)
- [Multiple carcinoid tumors of the small intestine]. (1995) (5)
- Somatostatin receptor subtype 2 expression and somatostatin receptor scintigraphy positivity in pancreatic serous cystadenomas. (2015) (5)
- Onset of rheumatoid arthritis following curative treatment of a somatostatinoma. (2002) (5)
- FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients. (2011) (5)
- Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. (2018) (5)
- Two year maintenance treatment of duodenal ulcer disease with ranitidine 150 mg: a prospective multicentre randomised study. GEMUD (Groupe d'Etude de la Maladie Ulcéreuse Duodénale). (1993) (5)
- 3485 Cystogastrostomy with 10 french stent entirely performed under endosonography guidance for pancreatic pseudocyst. (2000) (5)
- Benign Inflammatory Pancreatic Mucinous Cystadenomas Mimicking Locally Advanced Cystadenocarcinomas (2002) (5)
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors (2019) (5)
- [Natural history of non alcoholic and non familial chronic pancreatitis. Results of a multicentre study]. (1999) (5)
- Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study. (2015) (5)
- [Intraductal papillary mucinous tumor with pancreatobiliary and pancreatodigestive fistulae: a case report]. (2002) (5)
- [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. (1998) (5)
- Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. (2015) (5)
- [Immunohistochemical and ultrastructural heterogeneity of gastrointestinal stromal tumors]. (2001) (5)
- ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors (2012) (5)
- Non-branched microcysts of the pancreas on MR imaging of patients with pancreatic tumors who had pancreatectomy may predict the presence of pancreatic intraepithelial neoplasia (PanIN): a preliminary study (2019) (5)
- Tomographie par émission de positons et cancers digestifs (2008) (5)
- Pancreatic Intraepithelial Neoplasia in Patients With Intraductal Papillary Mucinous Neoplasms: The Interest of Endoscopic Ultrasonography (2013) (5)
- [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal]. (1994) (5)
- [Acute pancreatitis revealing Behçet disease]. (2005) (5)
- The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors (2019) (5)
- ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors (2022) (5)
- [Natural history of chronic alcoholic pancreatitis]. (2000) (4)
- Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study. (2015) (4)
- Frequency and type of lesions leading to erroneous diagnosis of intraductal papillary mucinous tumors of the pancreas (IMPT) (2001) (4)
- S1287 IgG4-Positive Plasma Cell Infiltration in the Digestive Tract Mucosa of Patients with Autoimmune Pancreatitis Is Neither Abundant Nor Specific (2009) (4)
- [Long-term efficacy and tolerability of omeprazole in 20 patients with severe Zollinger-Ellison syndrome]. (1989) (4)
- Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors (2018) (4)
- [Serous cystadenoma of the pancreas. An occasionally compressive tumor]. (2002) (4)
- Neuroendocrine tumors and CUP (2012) (4)
- Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract (2014) (4)
- A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. (2019) (4)
- [Economic analysis of maintenance treatment with ranitidine 150 mg in duodenal ulcer]. (1992) (4)
- Methylguanine DNA methyl transferase (MGMT) expression predicts response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs) (2012) (4)
- [Cystic and mucinous lesion in an antral ectopic pancreas]. (1998) (4)
- Bile duct obstruction caused by an eosinophilic papillary pseudotumor. (2003) (4)
- [Primary malignant melanoma of the esophagus: value of endoscopic ultrasonography in the assessment of extension]. (2001) (4)
- Gender-related differences in MEN 1 lesion occurrence and diagnosis : a cohort study of 734 cases from the Groupe d ’ étude des Tumeurs (2011) (4)
- A Long-Term (up to 6 years) Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and its Effect on Lipoprotein Lipase Deficiency (LPLD)-Induced Pancreatitis. (2016) (3)
- Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study (2018) (3)
- Renal effects of streptozocin: Preliminary results of the STREPTOTOX prospective study. (2014) (3)
- Liver transplantation for metastatic neuroendocrine tumors. (2014) (3)
- [Hepatic encephalopathy after injection of lanreotide, a somatostatin analog]. (1996) (3)
- 2331 Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel (2015) (3)
- Feasibility of large-scale eOSCES: the simultaneous evaluation of 500 medical students during a mock examination (2022) (3)
- Predictive Factors of Tumor Control in Patients With Well Differentiated Digestive Endocrine Carcinomas (WDEC) Treated With Lanreotide (2011) (3)
- [Permanent monocular visual defect, an unusual complication of migraine]. (1981) (3)
- Corrigendum to: Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis. [64 (9) 903–911] (2009) (3)
- [Weber Christian syndrome due to pancreaticomesenteric fistula secondary to acute alcoholic pancreatitis: treatment with pancreatic sphincterotomy alone]. (2003) (3)
- Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (3)
- Two-stage hepatectomy for metastases of digestive endocrine tumors (1998) (3)
- Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) (3)
- 2374 Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours (2015) (3)
- Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome (2021) (3)
- [Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency]. (2010) (3)
- [Systemic amylosis AL revealed by a hemorrhagic gastric pseudotumor]. (2007) (3)
- Is idiopathic pancreatitis an autoimmune disease (2003) (3)
- [Natural history and prognosis of pancreatic endocrine tumors]. (2003) (3)
- Comparative efficiency of lansoprazole and omeprazole on 24 hour intragastric ph measurement in 9 cases of zollinger ellison syndrome (1992) (3)
- Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs). (2015) (3)
- Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial (2017) (3)
- A 734-case cohort study from the GTE (Groupe d'étude des Tumeurs Endocrines). (2011) (3)
- A clear cell malignant gastrinoma of the pancreas with cytoplasmic accumulation of lipid droplets (2005) (3)
- Ductitis at Endoscopic Ultrasonography Has High Diagnosis Value in Autoimmune Pancreatitis (2011) (3)
- [Increase of serum alpha-fetoprotein in a patient with acinar cell carcinoma of the pancreas]. (1997) (2)
- Hypoxia activates pancreatic stellate cells: Development of an organotypic culture model of thick slices of normal human pancreas (2012) (2)
- Title: Impact of fluorodihydroxyphenylalanine-(18F) PET on management of adult patients with documented or occult digestive endocrine tumors Short title: FDOPA PET and digestive endocrine tumors (2009) (2)
- Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019) (2)
- [Malignant biliary papillomatosis: analysis of p53 expression]. (2004) (2)
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014) (2)
- 451PFinal analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) (2)
- 1136PDQUALITY OF LIFE (QOL) WITH LANREOTIDE AUTOGEL (LAN) VS. PLACEBO IN PATIENTS WITH ENTEROPANCREATIC NEUROENDOCRINE TUMOURS (EP-NETS): RESULTS FROM THE CLARINET PHASE III STUDY. (2014) (2)
- Pain and quality of life in patients with acute duodenal ulcer treated with ranitidine (1995) (2)
- C-MET expression as an independent prognostic marker in resected pancreatic ductal adenocarcinoma (PDAC): Proposition of a novel reliable immunostaining scoring method. (2014) (2)
- Pituitary adenoma in patients with multiple endocrine neoplasia type 1 - a cohort study. (2021) (2)
- Is Helicobacter pylori Eradication a Cost-Effective Treatment of Duodenal Ulcer Disease? (1997) (2)
- Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumours. (2021) (2)
- Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma (2017) (2)
- Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET) : A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data (2014) (2)
- 665 Contrast Harmonic Endoscopic Ultrasonography Is Able to Predict Aggressivity in Pancreatic Neuroendocrine Tumors (2015) (2)
- 897 Prognostic Heterogeneity Among Patients With Bone Metastases From Well-Differentiated Digestive Neuroendocrine Tumors (2013) (2)
- What does the term “Gastritis” mean for general practitioners? (1998) (2)
- Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. (2017) (2)
- [Efficacy of paromomycin sulfate (Humagel) in an AIDS infected patient with intestinal cryptosporidiosis]. (1992) (2)
- Splenic complications in chronic pancreatitis: Prevalence and risk factors in a medical-surgical series of 500 patients (1998) (2)
- Pancreatic intraepithelial neoplasia is associated with chronic pancreatitis due to serine protease inhibitor kazal type 1 and cystic fibrosis transmembrane conductance regulator mutations. (2010) (2)
- [Type II mixed cryoglobulinemia with cutaneo-nervous vasculitis during chronic hepatitis C]. (1991) (2)
- Branch Duct Intraductal Papillary Mucinous Neoplasms (BD-IPMN): Risk of Malignancy Still Present After 5 Years of Follow-up (2011) (2)
- [Gastric perforation by histoacryl extravasation as a complication of endoscopic sclerotherapy for bleeding Dieulafoy ulcer]. (2006) (2)
- 557 Alipogene Tiparvovec Gene Therapy Reduces the Risk of Acute Pancreatitis in Patients With Lipoprotein Lipase Deficiency (2012) (2)
- [The cost of endoscopy in gastroduodenal ulcer, or how to rationalize without rationing?]. (1993) (2)
- Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN). (2016) (2)
- M1291 Familial Pancreatic Cancer: BRCA2, CDKN2A and CDk 4 Gene Alterations and Screening of Relatives (2009) (2)
- Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study. (2021) (2)
- [A rare complication of chronic pancreatitis. Spontaneous rupture of the spleen]. (1987) (2)
- Fatal Bile Duct Necrosis: A Rare Complication of Transcatheter Arterial Chemoembolization in a Patient with Endocrine Hepatic Metastasis (2008) (2)
- Covid-19 crisis impact on the next generation of physicians: a survey of 800 medical students (2021) (2)
- A governmental program to encourage medical students to deliver primary prevention: experiment and evaluation in a French faculty of medicine (2020) (2)
- French reconnection: A conservative pancreato-enteric reconnection for disconnected pancreatic duct syndrome. (2020) (2)
- 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) (2)
- M1376 Digestive Venous Thrombosis (DVT) Occurring During Alcoholic Acute or Chronic Pancreatitis is Caused by Local Inflammation and Not by Thrombophilia (2010) (2)
- Su1314 Does Tobacco Influence the Natural History of Autoimmune Pancreatitis (2013) (2)
- Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs). (2015) (2)
- 68 Mortality Rate in Patients with Hereditary Pancreatitis (HP), Compared with the French General Population (2008) (2)
- Massive postoperative ascites following pancreatic cysts fenestration in a patient with von Hippel-Lindau disease. (2008) (1)
- Mo1345 Pancreas Divisum (PD), A Protective Factor Against Biliary Acute Pancreatitis (AP)? (2014) (1)
- S1159 Blood Flow Assessed By Perfusion CT Reflects Angiogenesis and Correlates with Prognostic Factors in pts with Pancreatic Endocrine Tumors (2008) (1)
- Could pancreatic grade 3 neuroendocrine tumors really behave similarly to neuroendocrine carcinomas following resection? (2020) (1)
- Role of FOXM1 in aggressive pancreatic / pulmonary neuroendocrine neoplasms and anti-tumor effect of the FOXM1 inhibitor Thiostrepton (2020) (1)
- 398 Benchmarking the Allosteric MEK Inhibitors UO126, AZD6244, AS703026, and GSK1120212 Shows Differences in Potency to Inhibit ERK Phosphorylation, Proliferation, and Invasion in Pancreatic Cancer Models (2012) (1)
- Bombesin (BBS) stimulation of gastrin release from gastrinoma cells in long term culture (1987) (1)
- [Calcic involution of a serous cystadenoma]. (2006) (1)
- eOSCE stations live versus remote evaluation and scores variability (2022) (1)
- [Update on the treatment of purulent ulcero-hemorrhagic rectocolitis]. (1988) (1)
- Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
- Methylguanine DNA methyl transferase (MGMT) expression to predict response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs). (2012) (1)
- Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) With Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients With Carcinoid Syndrome (CS): Results From the SymNET Study (2015) (1)
- NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors (2017) (1)
- Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET (2023) (1)
- 1134PDTREATMENT SATISFACTION, SYMPTOM CONTROL, AND QUALITY OF LIFE (QOL) WITH LANREOTIDE AUTOGEL (LAN) IN NEUROENDOCRINE TUMOUR (NET) PATIENTS WITH CARCINOID SYNDROME (CS): RESULTS FROM THE SYMNET STUDY. (2014) (1)
- [Digestive system carcinoid tumors: treatment]. (1999) (1)
- New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? (2012) (1)
- Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality. (2019) (1)
- Hepatic Arterial Embolization Versus Chemoembolization in Patients With Liver Metastases of a Digestive Neuroendocrine Tumors (2011) (1)
- Overall Survival (OS) Analysis of Sunitinib (SU) after Adjustment for Crossover (CO) in Patients with Pancreatic Neuroendocrine Tumors (NET) (2011) (1)
- [Complete resolution of insulin-dependent diabetes mellitus in a patient with autoimmune pancreatitis following treatment with corticosteroids]. (2010) (1)
- Contribution of Immune-Mediated Paraneoplastic Syndromes to Neurological Manifestations of Neuroendocrine Tumours: A Retrospective Study (2020) (1)
- Treatment satisfaction, symptom control and quality of life (QoL) with Lanreotide Autogel (LAN) in NET patients with carcinoid syndrome (CS): results from the SYMNET study. (2015) (1)
- Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregut‐like profile (2022) (1)
- 6575 Bevacizumab combined with chemotherapy in the treatment of advanced/metastatic gastro-entero-pancreatic tumours: interim safety results from the phase II BETTER study (2009) (1)
- [The role of endoscopic treatment of complications of chronic pancreatitis]. (2000) (1)
- QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors (2018) (1)
- Long Term Outcome of Biliary and Duodenal Stenting in Palliative Treatment of Patients with Unresectable Pancreatic Adenocarcinoma (2004) (1)
- [Plasma and urinary antithrombin III in the nephrotic syndrome in adults]. (1983) (1)
- Resecabilite des TIPMP degenerees : correlation TDM, chirurgicale et anatomo-pathologique a propos de 60 patients (2004) (1)
- SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts) (2014) (1)
- Obesity is a risk factor for pancreatic precancerous lesions (PanIN) (2014) (1)
- Comment on "predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine". (2014) (1)
- Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin (2022) (1)
- Prospective study of chemoembolization (CE) of liver metastases from endocrine tumors. A report of 15 cases (1994) (1)
- Can the efficacy of etoposide-platinum chemotherapy be predicted by p53/Rb status in grade 3 Neuroendocrine Neoplasms (G3 NEN)? (2020) (1)
- [Do not biopsy pseudopapillary and solid tumors of the pancreas!]. (2009) (1)
- Patient-reported outcomes associated with lanreotide Autogel (LAN-ATG) for symptom control of carcinoid syndrome in gastroenteropancreatic neuroendocrine tumour patients: results of SYMNET, a large International Multicentre Observational Study (2014) (1)
- [Suspected malignant cancer of the pancreas associated with pseudo-invasive duodenal hamartomas in a patient with Peutz-Jeghers syndrome]. (2007) (1)
- [Jejunal vipoma]. (2004) (1)
- [Desmoplastic small round cell tumour of the pancreas with breast metastasis]. (2009) (1)
- Gastric Juvenile Polyposis with High-Grade Dysplasia in Pachydermoperiostosis (2011) (1)
- [The journal enters the new millennium. A readership survey: why?]. (2000) (1)
- 2370 Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours (2015) (1)
- [Cholangiocarcinoma due to postradiation therapy cholangitis and chronic pancreatitis]. (2005) (1)
- Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment. (2023) (1)
- Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study. (2014) (1)
- Response to "Obesity potentiates the growth and dissemination of pancreatic cancer". (2010) (1)
- [Intraductal papillary mucinous tumours of the pancreas: imaging features]. (2005) (1)
- FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients. (2011) (1)
- [Neuro-lupus associated with Zollinger-Ellison syndrome with hepatic metastases: an incidental association?]. (1991) (1)
- Does laparoscopy still improve the accuracy of preoperative resectability staging of pancreatic head adenocarcinoma (PHA) at the era of spiral CT (sCT) and endoscopic ultrasonography (EUS) (2001) (1)
- Laparoscopic‐assisted liver transplantation: A realistic perspective (2022) (1)
- T1857 Morphological Versus Functional Imaging to Detect Recurrences After Resection of Liver Metastases of Digestive Endocrine Tumors (Lmdet) (2008) (0)
- IAP Membership Application Form 2010 (2010) (0)
- 756 Symptoms Are Earlier from Generation to Generation in Patients with Hereditary Pancreatitis (HP) (2009) (0)
- Pancreas; Endocrine Tumors (2019) (0)
- Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data (2015) (0)
- Echoendoscopy modifies classical predictive criteria of a biliary origin of acute pancreatitis: Prospective multicentre french study (2003) (0)
- 402 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells (2012) (0)
- Diagnostic accuracy of somatostatin receptor scintigraphy for preoperative localization of digestive endocrine tumors (1998) (0)
- Laparoscopic distal pancreatectomy should be the standard for neuroendocrine tumors. Analysis of a comparative study. (2019) (0)
- 7016 Endoscopic ultrasound fine-needle aspiration biopsy (eus-fnab): can the procedure be performed safely as out-patients? (2000) (0)
- The number of positive nodes accurately predicts recurrence after distal pancreatectomy for nonfunctioning neuroendocrine neoplasms (2020) (0)
- Antitumor activity of lanreotide autogel (LAN) in enteropancreatic net patients: The CLARINET open-label extension (OLE) study (2015) (0)
- Mo2029 Resection for Neuroendocrine Liver Metastases Give Excellent Long Term Survival but Very High Recurrence Rate. Analysis on 115 Liver Resections in a Tertiary Centre (2013) (0)
- Abstract 3261: Cellular effects of MEK inhibition in pancreatic cancer cell lines are not correlated with « classical » predictive markers of response to MEK inhibitors. (2013) (0)
- Pancretic endocrine tumors (PET) in von-hippel lindau (VHL) disease: Genotype/phenotype correlations (2003) (0)
- Tu1239 Postoperative Recurrence in Patients Operated on for Benign Intraductal Papillary Mucinous Neoplasms (IPMN) (2013) (0)
- A new biomarker to assess the grade of dysplasia in intraductal pancreatic mucinous neoplasms (IPMN) branch ducts (2012) (0)
- 300 Laparoscopic pancreatic resections the largest european single centre experience (2019) (0)
- Antitumor Activity of Lanreotide Autogel 120 mg in Enteropancreatic Neuroendocrine Tumour (NET) Patients: The Clarinet Open-Label Extension Study (2015) (0)
- Lack of long-term benefit of Helicobacter pylori eradication in patients with non ulcer epigastric pain (2000) (0)
- Characterization of pancreatic intra and extra-lobular fat by MALDI imaging: correlation with pancreatic precancerous lesion in human people (2017) (0)
- Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE) (2016) (0)
- [Chemoembolization, immunotherapy and hormone therapy of carcinoid and digestive neuroendocrine tumors]. (1995) (0)
- Tu1918 Correlation Between the 18F-FDG Uptake Assessed by PET/CT and Pathological Data in Well-Differentiated Digestive Neuroendocrine Tumors (2015) (0)
- 2228 Gastric neuroendocrine tumors (NETs): Data from the national French cohort of the Groupe d'Etude des Tumeurs Endocrines (GTE), CARGAS study (2015) (0)
- Detection of pancreatico-duodenal neuroendocrines tumors (NET): Conventional imaging is more sensitive than somatostatin receptor scintigraphy (SRS) (2001) (0)
- Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies. (2017) (0)
- Extensive liver surgery for endocrine metastases: Patients' outcome and diagnosis value of somatostatin receptor scintigraphy and morphological imaging during follow up (2007) (0)
- Lesions of pancreatitis in obese rats decrease after bariatric surgery (2015) (0)
- Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients (pts) with advanced neuroendocrine tumors: Multivariate analysis of progression-free survival from the RADIANT-2 trial. (2011) (0)
- S1362 Diagnostic Criteria in Autoimmune Pancreatitis (AIP): Hisort or Endoscopic Ultrasound (EUS)? (2010) (0)
- Prevalence and course of pancreatic lesions in von hippel-lindau (VHL) disease (1998) (0)
- Abstract 3260: Antiproliferative effects of PI3K-mTOR pathway inhibitors alone or in combination with MEK inhibitor GSK1120212 in pancreatic cancer cell lines are not correlated with molecular effects on ERK and S6 phosphorylation. (2013) (0)
- Tu1296 Recurrent Acute Pancreatitis in Israel – Genetic and Electrophysiological Aspects (2014) (0)
- De la pancréatite chronique aux pancréatites chroniques From the chronic pancreatitis to chronic pancreatites (2009) (0)
- Abstract B57: Effects of MEK inhibition alone or in combination with PI3K-mTOR pathway inhibitors in pancreatic ductal adenocarcinoma in vitro and on an innovative ex vivo fresh tumor tissue culture model (2016) (0)
- Relapsing auto-immune pancreatitis and treatment with rituximab: Results of a French cohort (2018) (0)
- Tu1886 Adipose Tissue Is Toxic for Pancreatic Parenchyma: Co-Culture Model of Pancreatic Tissue and Visceral Adipose Tissue (2015) (0)
- Impact of surgery and chemotherapy on survival in patients with advanced cholangiocarcinoma: A multivariate analysis in a cohort of 242 consecutive patients. (2006) (0)
- [Questions for professor Philippe Ruszniewski]. (2006) (0)
- Evaluation of tumor response to targeted therapies in precision-cut slices of human pancreatic neuroendocrine tumors (2014) (0)
- [Metastatic transitional cell carcinoma with high CA 19.9 serum levels]. (2007) (0)
- Iconography : Imaging IPMN: Take home messages and news (2011) (0)
- Contents Vol. 96, 2012 (2012) (0)
- Incidence of acute pancreatitis due to antiretroviral treatment (2003) (0)
- W1951 Recurrence After Surgical Resection of Gastrinoma: Who, When, Where and Why ? (2009) (0)
- S1278 Is the Search for Serum Antibodies to Carbonic Anhydrase II Helpful for the Diagnosis of Auto-Immune Pancreatitis? (2009) (0)
- Tu1834 Orexins Exert a PRO-Apoptotic Effect on Digestive Human Neuroendocrine Tumors (NET) in an Ex-Vivo Culture Model of Tissue Slices (2012) (0)
- Efficacy of alkylating agent rechallenge after therapeutic pause in metastatic pancreatic neuroendocrine tumors (PanNET). (2020) (0)
- Correction to: Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging (2020) (0)
- Zollinger-Ellison syndrome . syndrome in a case of of paraneoplastic Cushing ' s Long acting somatostatin treatment (2006) (0)
- Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) (0)
- Metabolic state may define and predict resistance to mTOR-targeting therapies in pancreatic neuroendocrine tumors (2016) (0)
- Contents Vol. 80, 2004 (2005) (0)
- Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors (2014) (0)
- Efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-fluorouracil (5-FU) in endocrine carcinomas: A retrospective multicentric study from the Groupe des Tumeurs Endocrines (GTE). (2009) (0)
- [Verner-Morrison syndrome revealing a ganglioneuroblastoma in an adult]. (2008) (0)
- [Spontaneous rupture of the spleen in staphylococcal septicemia]. (1983) (0)
- 327 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki67 Index Predict Response to Temozolomide in Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) (2014) (0)
- Inhibition By the Somatostatin Analog Sms 201-995 of Gastrinoma Cells in Culture (1988) (0)
- [Cell receptors modulating epithelial transport]. (1990) (0)
- Subject Index Vol. 80, 2004 (2005) (0)
- Recurrent Acute Pancreatitis in Israel (2011) (0)
- [PET and digestive cancers]. (2008) (0)
- Comparative analysis between Sendai guidelines and the European experts consensus statement on BD-IPMN of the pancreas (2015) (0)
- A Phase II Trial of Bevacizumab with Capecitabine in Progressive, Metastatic Well-Differentiated Digestive Endocrine Tumors (Better Study) (2012) (0)
- No volume effect on acute pancreatitis mortality: a systematic review of national register 2013-2014 (2017) (0)
- 6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET) (2011) (0)
- Prolonged endogenous hypergastrinemia in man: Influence on epithelial cell kinetics and tumor occurrence in the colon (1992) (0)
- [Anomalies of fundic argyrophil cell proliferation (enterochromaffin-like cells) in Zollinger-Ellison syndrome]. (1991) (0)
- Carcinoid heart disease in patients with midgut neuroendocrine tumours (2023) (0)
- FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors (2022) (0)
- Tumeurs endocrines digestives (1996) (0)
- 722 Long Term Outcome of Patients With Auto-Immune Pancreatitis (2010) (0)
- OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer? (2016) (0)
- 4699 Malignant intraductal papillary mucinous tumors of the pancreas: prognostic factors after surgery. (2000) (0)
- 475 Pancreas Divisum Is Not a Cause of Pancreatitis By Itself (2009) (0)
- Subject Index Vol. 91, 2010 (2010) (0)
- Postoperative recurrence in patients operated on for benign intraductal papillary mucinous neoplasms (IPMN) (2013) (0)
- Stimulation by Bombesin of Gastrin Release from Human Gastrinoma Cells in Long‐Term Cultures (1988) (0)
- Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models. (2015) (0)
- W1134 Enteral CT Scan Has a High Diagnostic Accuracy for the Detection of Endocrine Tumors of the Small Bowel (2010) (0)
- [Pseudo Zollinger-Ellison syndrome in a patient with duodenal stenosis caused by tuberculosis]. (2005) (0)
- Obesity-induced pancreatopathy in rats is reversible after bariatric surgery (2018) (0)
- W1415 Natural History and Morphological Evolution of Pancreatic Serous Cystadenoma (sc) (2008) (0)
- Parenchyma-sparing pancreatectomies for pancreatic neuroendocrine tumors (2015) (0)
- [From the chronic pancreatitis to chronic pancreatites]. (2009) (0)
- Long-term outcome of pancreatic neuroendocrine tumours (PNET) in von Hippel-Lindau (VHL) compared to sporadic PNET : implications for management (2014) (0)
- [Chronic pancreatitis]. (2002) (0)
- W1130 Magnetic Resonance Imaging (MRI) vs Endoscopic Ultrasonography (EUS) for the Detection of ≥ 10-mm Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (Men1): A Multicentric Study by the Gte (2010) (0)
- [Systemic mastocytosis with digestive involvement]. (1991) (0)
- [Basal blood gastrin is normal during the long-term preventive treatment of recurrence of duodenal ulcer with ranitidine 150 mg daily]. (1990) (0)
- 1062 - Cftr Mutations Relevance on Pancreatitis Outcome: Genotype-Phenotype Correlation and Impact of Associated Factors (2018) (0)
- Tu1894 Chronic Pancreatitis Occurs in Obese Rats and Is Reduced After Bariatric Surgery (2015) (0)
- Twoyear maintenance treatment of duodenal ulcer disease with ranitidine 150 mg : a prospective multicentre randomised study TABLE II Patients ' follow up during the two years of study Placebo Ranitidine (2006) (0)
- Genomic and transcriptomic characterization of aggressive well differentiated pancreatic neuroendocrine tumors (2018) (0)
- Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study. (2022) (0)
- 255 laparoscopic pancreatic resections: single centre experience (2016) (0)
- P.337 Anticorps anti-anhydrase carbonique de type II : une aide au diagnostic de pancréatite auto-immune ? (2009) (0)
- 1131 MALDI Imaging of Ubiquitin: A New Tool to Assess the Grade of Dysplasia in Intraductal Pancreatic Mucinous Neoplasms (IPMN) (2012) (0)
- MEK inhibition blocks S-phase entry in K-Ras mutated pancreatic cancer cell lines (2012) (0)
- Overview of neuroendocrine liver metastases treatment (2012) (0)
- Patologia surrenalica nella MEN-1. Analisi di 715 casi dal database “Groupe d’étude des tumeurs endocrines” (2012) (0)
- Gene symbol: Spink1-Omim 167790. Disease: Hereditary pancreatitis. (2003) (0)
- Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors (2023) (0)
- Joint Meeting of the 11th Meeting of the International Association of Pancreatology (IAP) and the 35th Annual Meeting of the Japan Pancreas Society (JPS) (2004) (0)
- Longacting somatostatin treatment ofparaneoplastic Cushing's syndrome inacaseofZollinger-Elliso n syndrome (1988) (0)
- Surgery for Pancreatic Neoplasms: How Accurate are our Indications? (2016) (0)
- Contents Vol. 91, 2010 (2010) (0)
- Gemcitabine-oxaliplatin (GemOx) combination followed by chemoradiotherapy (CRT) in borderline pancreatic adenocarcinoma (BPC). (2014) (0)
- Contents Vol. 105, 2017 (2017) (0)
- Neuroendocrine Tumor Patient Experience and Disease Burden: Results From the First Global NET Patient Survey—A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals (2015) (0)
- CFTR mutations relevance on pancreatitis outcome: genotype-phenotype correlation and impact of associated factors (2018) (0)
- Sa1388 - Auto-Immune Pancreatitis Relapses, the Rituximab Experience: Results of a French Cohort (2018) (0)
- Natural history of pancreatitis associated with SPINK1 mutations (2017) (0)
- Iconographies supplémentaires de l'article : Massive postoperative ascites following pancreatic cysts fenestration in a patient with von Hippel-Lindau disease (2014) (0)
- Gastroenteropancreatic neuroendocrine tumors (neoplasms) (2014) (0)
- Solid and pseudopapillary tumours of the pancreas: Are the epidemiology and imaging features changing? (2012) (0)
- O6-methylguanine DNA methyltransferase (MGMT) expression and Ki67 index predict response to temozolomide in patients with well differentiated pancreatic neuroendocrine tumors (WDPNET) (2014) (0)
- [Anatomo-clinical conference. Hôpital de la Pitié-Salpêtrière. Case No. 4-1994. Chronic diarrhea in a patient with lupus]. (1994) (0)
- Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors (2015) (0)
- OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES) (2006) (0)
- Mo1416 Fatty Pancreas Is a Risk Factor for PanIN Lesions (2013) (0)
- Value of Endoscopic Ultrasound Guided Fine Needle Aspiration Biopsy (EUS-FNAB) in the Diagnosis of Solid Pancreatic Masses: Prospective Analysis Using a Standardized ThinPrep® Method (2006) (0)
- W1133 Are Recist Criteria Accurate to Evaluate Tumor Response to Targeted Therapies in Patients With Digestive Endocrine Tumors (Dets) (2010) (0)
- W1403 Pancreatic Lesions of Dysplasia (Panin) Are Observed in Hereditary Pancreatitis (HP): A Pathological Study (2008) (0)
- Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus. (2012) (0)
- Mo1404 Solid Pancreatic Tumors in Young Patients (< 40 Years Old): What Is Your Diagnosis ? (2013) (0)
- Endoscopic diagnosis and treatment of neuroendocrine tumors (2021) (0)
- Diagnosis of pancreatic masses: The role of endoscopic ultrasound guided biopsy (1998) (0)
- 720 Smoking and the Course of Chronic Pancreatitis: A Dose-Dependent Relationship (2010) (0)
- [Diffuse primary fat replacement of the pancreas: an unusual cause of steatorrhea]. (2007) (0)
- Comprar Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract | Eric Raymond | 9782817804293 | Springer (2014) (0)
- W1413 Proteomic Assessment of Markers for Malignancy in the Mucus of Intraductal Papillary Mucinous Neoplasms of the Pancreas (IPMN) (2008) (0)
- 12 Pancreatic Involvement in Von Hippel-Lindau Disease (2004) (0)
- [Adjuvant treatment of endocrine digestive tumors]. (1994) (0)
- O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs (2021) (0)
- 6514 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial (2009) (0)
- Cellular effects of MEK inhibition in pancreatic cancer cell lines are not correlated with « classical » predictive markers of response to MEK inhibitors (MEKi) (2013) (0)
- Laparoscopic distal pancreatic resection: Is there a learning curve? (2012) (0)
- Android obesity is a risk factor for IPMN with high grade of dysplasia (2016) (0)
- Natural History of Small Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: An Observational Bi-Centric Study (2013) (0)
- Decreased pS6 expression under MEK inhibitor (MEKi) correlates with response to MEKi alone or combined with PI3Ki-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models (2015) (0)
- 898 Is a « Watch and Wait » Strategy Justified in Patients With Small Non-Functioning Pancreatic Neuroendocrine Tumors ? (2013) (0)
- Interview du Pr Philippe Ruszniewski (2019) (0)
- HYPNOSIS FOR INTRACTABLE VOMITING (1987) (0)
- 9th Meeting of the Spanish Bilio-Pancreatic Club (2006) (0)
- Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals. (2018) (0)
- 870 Hypoxia Activates Pancreatic Stellate Cells: Development of an Organotypic Culture Model of Thick Slices of Normal Human Pancreas (2012) (0)
- Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study (2014) (0)
- EPC Society News (2002) (0)
- Therapeutic management of GEP ET (2007) (0)
- Familial pancreatic cancer (FPC): Report of a French series and identification a novel genetic alteration of p12 (2014) (0)
- O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. (2020) (0)
- [Therapeutic management of duodenal ulcer except in emergency cases: antisecretory treatment]. (1996) (0)
- Trypsinogen cationic gene mutations in patients with non-alcoholic non-hereditary chronic pancreatitis: Results of a european multicentre study (2001) (0)
- W1405 Heterogeneity in the Expression of Prognostic Markers in Liver Metastases of Pancreatic Endocrine Tumours (2008) (0)
- Efficacy of Everolimus to prevent hypoglycemia in patients with metastatic insulinomas: for the French group of endocrine tumors (GTE-Renaten) (2012) (0)
- Effects of Esomeprazole on Acid Output in Patients with Zollinger-Ellison Syndrome (ZES) and Idiopathic Gastric Acid Hypersecretion (IGH): 6-Month Results (2005) (0)
- Primary endocrine tumors of the liver: Features and prognosis (2003) (0)
- M1390 Prevalence of Depression Among Patients With Alcoholic Pancreatitis (2010) (0)
- Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) : A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS) (2014) (0)
- Are recist criteria adequate in assessing the response to therapy in metastatic NEN? (2021) (0)
- 568P FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors (2021) (0)
- Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. (2019) (0)
- Precursor lesions of gastroenteropancreatic neuroendocrine tumors (2007) (0)
- Well differentiated pancreatic neuroendocrine tumors (WDPNET) G3: Does the Ki67 really do it all? (2016) (0)
- W1135 Biopsy of Pancreatic Endocrine Tumors (PETs) or of Their Liver Metastases Allows Accurate Characterization: A Comparison With Surgical Specimen Pathology (2010) (0)
- 53 From Pancreatic Intraepithelial Neoplasia (PanIN) to Intraductal Papillary Mucinous Neoplasms (IPMN): What is the Significance of Endoscopic Ultrasound Findings? (2010) (0)
- Predictors and Patterns of Recurrence after Surgery for Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Implications for Follow-up Strategy (2020) (0)
- PS04.05 ElevatION NET 201:Ph II Study of PDR001 in Metastatic, Well Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly Differentiated GEP NEC: Topic: Medical Oncology (2017) (0)
- ULCERE GASTRO-DUODENAL DE L'ADULTE (1996) (0)
- 569P Causes of death in patients with metastatic digestive neuroendocrine tumours (2021) (0)
- W1411 In Situ Detection of Vhl/HIF Pathway Proteins Identifies a Pancreatic Endocrine Microadenomatosis in Patients with a Von Hippel-Lindau Disease (Vhl) (2008) (0)
- 404 Acute Pancreatitis (AP) in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas (IPMN): Frequency, Severity and Correlation with Tumors Characteristics (2008) (0)
- Pain and Quality of Life in Acute Duodenal Ulcer ( DU ) : Effect of Ranitidine (2006) (0)
- Fatty pancreas is a risk factor for PanIN lesions (2013) (0)
- Abstracts of the 6th Annual ENETS Conference, Granada, Spain, March 5–7, 2009 (2009) (0)
- Simplified LV5FU2-irinotecan (FOLFIRI) in the first-line therapy of well-differentiated endocrine carcinomas of the duodeno- pancreatic area: Preliminary results of the FFCD 0302 phase II trial with GTE participation (2007) (0)
- 75INTOOLS TO EVALUATE TUMOUR RESPONSE TO THERAPY: IMAGING. (2014) (0)
- Liver-Directed Therapies in Neuroendocrine Tumors (2014) (0)
- 1044 Obesity Is a Risk Factor for Pancreatic Precancerous Lesions (2014) (0)
- Abstract 2677: Decrease in phospho-S6 expression under MEK inhibitor (MEKi) treatment as a potential predictive biomarker of response to MEKi alone or in combination with PI3K-mTOR pathway inhibitor in pancreatic adenocarcinoma in vitro and ex vivo models (2015) (0)
- Pancreatitis in patients with lipoprotein lipase deficiency and the effect of alipogene tiparvovec (AAV1-LPLS447X gene therapy) (2012) (0)
- Sa1149 Possible Predictors of Patient-Reported Satisfaction With Diarrhea Control Associated With Lanreotide Depot (LAN) Treatment for Carcinoid Syndrome (CS) in Gastroenteropancreatic Neuroendocrine Tumor (NET) Patients (2014) (0)
- [Gastroentérologie Clinique et Biologique: the team moves on]. (2001) (0)
- Human Gastrinoma Culture As a Model for Gastrin Biosynthesis and Regulation (1988) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Philippe B. Ruszniewski?
Philippe B. Ruszniewski is affiliated with the following schools:
